相关实验视频

Updated: Jul 28, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在患有晚期和复发性子宫内膜癌的患者中使用Selinexor

Giorgio Bogani¹, Bradley J Monk², Robert L Coleman³

¹Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Current problems in cancer

|June 4, 2023

概括

塞利尼克索尔是一种口服的EXPORTIN 1 (XPO1) 抑制剂,在晚期子宫内膜癌中表现有前途. 虽然整体上没有显著降低进展风险,但它在TP53野生型瘤中显示出明显的益处.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
临床试验临床试验

背景情况:

塞利尼克索是口服抑制剂Exportin 1 (XPO1),一种蛋白质通常在子宫内膜癌中过度表达.
抑制XPO1导致瘤抑制剂的核定位和亡诱导,之前的试验显示在子宫内膜癌中具有抗瘤活性.

研究的目的:

在一线化疗后,评估selinexor作为晚期子宫内膜癌的维持疗法.
调查selinexor在特定分子子组的疗效,特别是TP53野生类型.
探索selinexor与PARP抑制剂和免疫检查点抑制剂的潜在组合.

主要方法:

从III期SIENDO试验 (Selinexor in ENDOmetrial Cancer) 的初步结果进行分析.
在先进的子宫内膜癌患者中评估selinexor对疾病进展或死亡风险的影响.
对TP53野生类型分子子组的疗效评估.

主要成果:

塞利尼克索维护疗法显示,疾病进展或死亡风险减少了30%,但不显著.
在TP53野生型子组中,塞利尼克索表现出更明显的抗瘤作用,将进展或死亡风险降低约60%.

结论:

塞利尼克索尔在晚期子宫内膜癌中显示出作为维持治疗的潜力,特别是在TP53野生型子组中.
需要进一步的试验 (SIENDO,XPORT-EC) 来确认在更广泛的患者群体中的益处和风险.
临床前数据表明与PARP抑制剂和免疫检查点抑制剂的潜在协同作用,需要进一步临床研究.

关键词:

这是子宫内膜癌的癌症.维护维护维护维护这就是Selinexor.一个XPO1一个XPO1一个XPO1 p53野生类型的野生类型

更多相关视频

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...